How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing Via CTDMO Services
Source: MilliporeSigma
Covid-19 vaccines have demonstrated the clinical potential of mRNA-Lipid Nanoparticle formulations. To enable the development of next-generation lipid-based drug delivery systems, expertise and manufacturing capabilities are critical. Relying on more than 20 years of experience in GMP lipid/LNP manufacturing, MilliporeSigma aims to support pioneers in nucleic acid modalities to bring life-changing medicines from preclinical to commercial manufacturing.
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
MilliporeSigma
This website uses cookies to ensure you get the best experience on our website. Learn more